← Oncology Approval Tracker

FDA DECISION ·

Enhertu

fam-trastuzumab deruxtecan-nxki · Daiichi Sankyo

Accelerated approvalNew or expanded indicationTumor-agnostic solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with unresectable or metastatic HER2 IHC 3+ solid tumors previously treated systemically and without satisfactory alternatives.

LAMPGEN ANALYSIS

Why it matters

The antibody–drug conjugate gained a tumor-agnostic indication anchored to strong HER2 expression.

What research teams should watch

Do not substitute other HER2 categories for IHC 3+; make early evaluation of cough or breathlessness part of follow-up.

PRIMARY RECORDS

Sources